News One of J&J's blockbuster depression hopes has flamed out Johnson & Johnson has halted the development of aticaprant as a treatment for major depressive disorder, blowing a hole in its late-stage pipeline.
News Denali's ALS programme suffers another setback Prospects for Denali Therapeutics' experimental medicine for amyotrophic lateral sclerosis have taken another tumble.
News Biogen, Apple study finds smart devices can track cognition An observational study backed by Biogen has suggested that Apple smartphones and watches may be able to spot the signs of mild cognitive impairment.
News Trump's NIH pick closer to role as court blocks budget cuts NIH director nominee Jay Bhattacharya was quizzed closely on vaccines and budget cuts by the Senate HELP committee but seems odds on to take the job.
News Enhertu extends survival in advanced gastric cancer Data from a phase 3 trial of Enhertu in advanced HER2-positive gastric cancer could support wider use as a second-line therapy.
News Sofinnova raises €1.2bn to back 'up to 60' companies Sofinnova has raised €1.2bn that it says could support 50 to 60 companies across biotech, medtech, industrial biotech, and digital medicine.
News Aspen, Bambusa close IPOs as Corxel takes SPAC route Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.